1.0Kuwait News Gazettehttps://kuwaitnewsgazette.comkgadminhttps://kuwaitnewsgazette.com/author/kgadmin/rich600338<blockquote class="wp-embedded-content" data-secret="DQyOhJsvv6"><a href="https://kuwaitnewsgazette.com/zenas-biopharma-announces-first-patient-dosed-in-phase-3-clinical-study-of-obexelimab-for-the-treatment-of-immunoglobulin-g4-related-disease-igg4-rd/">Zenas BioPharma Announces First Patient Dosed in Phase 3 Clinical Study of Obexelimab for the Treatment of Immunoglobulin G4-Related Disease (IgG4-RD)</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="https://kuwaitnewsgazette.com/zenas-biopharma-announces-first-patient-dosed-in-phase-3-clinical-study-of-obexelimab-for-the-treatment-of-immunoglobulin-g4-related-disease-igg4-rd/embed/#?secret=DQyOhJsvv6" width="600" height="338" title="“Zenas BioPharma Announces First Patient Dosed in Phase 3 Clinical Study of Obexelimab for the Treatment of Immunoglobulin G4-Related Disease (IgG4-RD)” — Kuwait News Gazette" data-secret="DQyOhJsvv6" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script> /*! This file is auto-generated */ !function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document); </script> Global Phase 3 INDIGO study will evaluate the efficacy and safety of obexelimab in patients with IgG4-RD, a chronic and serious fibroinflammatory disease typically affecting multiple organs IgG4-RD is the first of several potential disease indications to be pursued for obexelimab given its unique non-depleting, B-cell inhibition WALTHAM, Mass., Jan. 11, 2023 (GLOBE NEWSWIRE) — […]https://ci4.googleusercontent.com/proxy/u59vDKj76deBVVtEfu4DfgHUUNXr57ExL35-cViS4kBdLRXF0YNCelwtyHgjQPPjQJwc3yGyNMftvpzrV31lrrnPc6mFNojbUWtDnrSQRMTNE964nrrmKNHxvhXVsWcgTpuA3B_9IrAUbGzFJ1uHaP-UyV5TWBzy4A0V1d2YuMsJDAKvHQt34f4wSMSUkWfq8BLnYw=s0-d-e1-ft#https://ml.globenewswire.com/media/MWU4NTM1NjMtZjZiOS00YjdhLTlhMjktODI0OTBhZmZmMTUyLTEyMTkzNDg=/tiny/Zenas-BioPharma-USA-LLC.png